Performance of IBRX Immunitybio | 157.6% in 12m
Compare IBRX with Indices, Sectors and Commodities ✔ like Oil, Gas, Gold, Yields and Bonds. Who outperforms?
Compare Immunitybio with its related Sector/Index XBI
Performance Duell IBRX vs XBI
| TimeFrame | IBRX | XBI |
|---|---|---|
| 1 Day | -1.29% | -1.52% |
| 1 Week | -11.4% | 1.45% |
| 1 Month | 45.2% | 10.08% |
| 3 Months | 61.7% | -1.30% |
| 6 Months | 88.9% | 24.09% |
| 12 Months | 157.6% | 6.83% |
| YTD | 46.0% | 1.05% |
| Rel. Perf. 1m | 3.57 | |
| Rel. Perf. 3m | 4.47 | |
| Rel. Perf. 6m | 4.62 | |
| Rel. Perf. 12m | 8.78 |
Is Immunitybio a good stock to buy?
Partly, yes. Based on ValueRay Analyses, Immunitybio (NASDAQ:IBRX) is currently (May 2024)
ok to buy, but has to be watched. It has a Growth Technical Rating of 3.84 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBRX as of May 2024 is 7.76. This means that IBRX is currently overvalued and has a potential downside of 1.44% (Sold with Premium).
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of IBRX as of May 2024 is 7.76. This means that IBRX is currently overvalued and has a potential downside of 1.44% (Sold with Premium).
Is IBRX a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 1
- Sell: 0
- Strong Sell: 0
Values above 0%: IBRX is performing better - Values below 0%: IBRX is underperforming
Compare IBRX with Broad Market Indices
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| US S&P 500 | SPY | -13.00% | 38.23% | 71.50% | 129.27% |
| US NASDAQ 100 | QQQ | -13.32% | 36.21% | 72.83% | 122.43% |
| US Dow Jones Industrial 30 | DIA | -12.75% | 39.70% | 74.11% | 135.67% |
| German DAX 40 | DBXD | -11.12% | 40.01% | 71.73% | 143.20% |
| UK FTSE 100 | ISFU | -12.90% | 35.61% | 72.65% | 142.93% |
| Shanghai Shenzhen CSI 300 | CSI 300 | -12.51% | 40.43% | 86.77% | 164.86% |
| Hongkong Hang Seng | HSI | -13.51% | 22.30% | 85.20% | 162.99% |
| Japan Nikkei 225 | EXX7 | -12.42% | 44.28% | 77.11% | 146.85% |
| India NIFTY 50 | INDA | -13.78% | 41.96% | 71.31% | 127.76% |
| Brasil Bovespa | EWZ | -11.27% | 41.87% | 92.65% | 144.87% |
IBRX Immunitybio vs. Sectors
| Symbol | 1w | 1m | 6m | 12m | |
|---|---|---|---|---|---|
| Communication Services | XLC | -12.55% | 41.21% | 71.71% | 121.80% |
| Consumer Discretionary | XLY | -11.83% | 39.89% | 82.10% | 138.75% |
| Consumer Staples | XLP | -12.41% | 40.10% | 74.57% | 151.55% |
| Energy | XLE | -12.83% | 45.17% | 74.93% | 134.22% |
| Financial | XLF | -13.35% | 39.93% | 66.96% | 124.92% |
| Health Care | XLV | -13.35% | 39.86% | 74.58% | 144.33% |
| Industrial | XLI | -11.50% | 41.13% | 69.56% | 129.87% |
| Materials | XLB | -11.76% | 41.57% | 73.07% | 137.98% |
| Real Estate | XLRE | -13.60% | 37.13% | 80.09% | 146.72% |
| Technology | XLK | -13.93% | 35.14% | 74.23% | 121.98% |
| Utilities | XLU | -12.86% | 34.60% | 70.33% | 144.39% |
| Aerospace & Defense | XAR | -12.43% | 36.80% | 74.64% | 133.15% |
| Biotech | XBI | -12.81% | 35.08% | 64.80% | 150.75% |
| Homebuilder | XHB | -11.94% | 38.16% | 58.63% | 106.73% |
| Retail | XRT | -10.88% | 38.47% | 68.79% | 128.08% |
Does Immunitybio outperform its market, is IBRX a Sector Leader?
Yes, over the last 12 months Immunitybio (IBRX) made 157.58%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months IBRX made 61.73%, while XBI made -1.30%.
Yes, over the last 12 months Immunitybio (IBRX) made 157.58%, while its related Sector, the SPDR S&P Biotech (XBI) made 6.83%.
Over the last 3 months IBRX made 61.73%, while XBI made -1.30%.
| Period | IBRX | XBI | S&P 500 |
|---|---|---|---|
| 1 Month | 45.16% | 10.08% | 6.93% |
| 3 Months | 61.73% | -1.30% | 6.91% |
| 12 Months | 157.58% | 6.83% | 28.31% |